INS and myeloid sarcoma: Similarly, in MS patients there was a higher percentage of insulin therapy [31 (31.3%) vs. 10 (9.3%), p-value 0.041], and oral hypoglycemic drug therapy [57 (57.6%) vs. 31 (29%), p-value 0.022].